Hostname: page-component-cd9895bd7-mkpzs Total loading time: 0 Render date: 2024-12-28T18:02:45.965Z Has data issue: false hasContentIssue false
  • English
  • Français

Inhibition of head and neck metastatic and/or recurrent cancer by local administration of multi-cytokine inducer OK-432

Published online by Cambridge University Press:  29 June 2007

Satoshi Kitahara ,
Makoto Ikeda ,
Tetsuzo Inouye ,
Takeshi Matsunaga ,
Kengo Yamaguchi ,
Etsuyo Takayama ,
Gerald B. Healy  and
Mamoru Tsukuda
Satoshi Kitahara
Affiliation:
Department of Otolaryngology - Head and Neck Surgery, National Defense Medical College, Saitama.
Makoto Ikeda*
Affiliation:
Department of Otolaryngology - Head and Neck Surgery, National Defense Medical College, Saitama.
Tetsuzo Inouye
Affiliation:
Department of Otolaryngology - Head and Neck Surgery, National Defense Medical College, Saitama.
Takeshi Matsunaga
Affiliation:
Department of Otolaryngology - Head and Neck Surgery, National Defense Medical College, Saitama.
Kengo Yamaguchi
Affiliation:
Department of Otolaryngology - Head and Neck Surgery, National Defense Medical College, Saitama.
Etsuyo Takayama
Affiliation:
Department of Otolaryngology - Head and Neck Surgery, National Defense Medical College, Saitama.
Gerald B. Healy
Affiliation:
Department of Otology and Laryngology, Harvard Medical School, Boston, MA, USA
Mamoru Tsukuda
Affiliation:
Department of Otolaryngology, School of Medicine, Yokohama-city University, Yokohama, Japan.
*
Address for correspondence: Dr Makoto Ikeda, M.D., Ph.D., Undersea Medical Centre, 2-7-1 Nagase, Yokosuka-city, Japan. Fax: Japan (81)-429955330
Get access Rights & Permissions [Opens in a new window]

Abstract

The multi-cytokine inducer OK-432 is a pulverized preparation of the low-virulence SU strain of Streptococcus pyogenes of human origin. A reduction of the tumour mass in the OK-432-injected areas was observed in 11 out of 13 patients with metastatic and/or recurrent head and neck cancer. Complete response (CR), partial response (PR) and minor response (MR) were noted in six, three and two cases respectively. OK-432 local administration therapy could create a new strategy for cancer therapy.

Keywords

Head and neck neoplasmsChemotherapyOK-432
Type
Main Articles
Information
The Journal of Laryngology & Otology , Volume 110 , Issue 5 , May 1996 , pp. 449 - 453
Copyright
Copyright © JLO (1984) Limited 1996

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Fujimori, M., Sugenoya, A., Kobayashi, S., Masuda, H., Komatsu, M., Takahashi, S., Shimizu, T., Tsuchiya, S., Iida, F. (1989) Local immunotherapy for breast cancer: case with advanced breast cancer improved by combined local injection therapy with OK-432 and rIL-2. Japanese Journal of Cancer Chemotherapy 16: 2760–2763.Google ScholarPubMed
Fujioka, T., Ishikura, K., Tanji, S., Okamoto, T., Koike, H., Aoki, H., Ohhori, T., Kubo, T. (1990) Combined effects of intraperitoneal administration of recombinant interleukin-2 and Streptococcal preparation OK-432 in murine tumours. International Journal of Immunopharmacology 12: 419–426.CrossRefGoogle Scholar
Hirakawa, H., Akimoto, M., Matano, S., Abe, M., Mori, S. (1989) A case with multiple liver metastasis from breast cancer successfully treated by local injection of OK-432 (400KE) and trans-arterial infusion of rIL-2. Biotherapy 3: 742–745.Google Scholar
Ichimura, O., Suzuki, S., Saito, M. (1985). Augmentation of interleukin 1 and interleukin 2 production by OK-432. International Journal of Immunopharmacology 7: 263–268.CrossRefGoogle ScholarPubMed
Ikeda, M., Tsuru, S., Shinomiya, N., Taniguchi, M., Fujisawa, T., Zinnaka, Y. (1985) Activation of peritoneal macrophages induced by OK-432. Journal of National Defense Medical College 10: 115–119.Google Scholar
Ishii, Y., Yamaoka, H., To, K., Kikuchi, K. (1976) Inhibition of tumour growth in vivo by macrophages from rat treated with a Streptococcal preparation, OK-432. Gann 67: 115–119.Google ScholarPubMed
Kitahara, S., Ikeda, M., Tanabe, T., Sakata, J., Inouye, T. (1989) Treatment of head and neck cancer by OK-432 local injection. Therapeutic Research 10: 383–391.Google Scholar
Kokunai, I., Mori, T., Yayoi, E., Matsuura, N., Kamimae, G. (1985) Correlation between anti-tumour effect and delayed hypersensitivity induced by topically applied OK-432 with histological findings. Japanese Journal of Surgery 86: 258–265.Google ScholarPubMed
Misaki, T., Watanabe, Y., Iida, Y., Hidaka, A., Kasagi, K., Fukushima, H., Konishi, J. (1992) Recruitment of T lymphocytes and induction of tumour necrosis factor in thyroid cancer by a local immunotherapy. Cancer Immunology Immunotherapy 35: 92–96.CrossRefGoogle ScholarPubMed
Mizutani, Y., Nio, Y., Yoshida, O. (1991) The Streptococcal preparation OK-432 specificity augments the susceptibility of human urinary bladder tumour cells to autologous peripheral blood lymphocytes. Cancer 69: 2999–3007.3.0.CO;2-A>CrossRefGoogle Scholar
Ogita, S., Tsuto, T., Deguchi, E., Tokiwa, K., Nagashima, M., Iwai, N. (1991) OK-432 therapy for unresectable lymphangiomas in children. Journal of Pediatric Surgery 26: 263–270.CrossRefGoogle ScholarPubMed
Oshimi, K., Kano, S., Takaku, F., Okaumura, K. (1980a) Augmentation of mouse natural killer cell activity by a Streptococcal preparation, OK-432. Journal of the National Cancer Institute 65: 1265–1270.Google ScholarPubMed
Oshimi, K., Wakasugi, H., Seki, H., Kano, S. (1980b) Streptococcal preparation OK-432 augments cytotoxic activity against an erythroleukemic cell line in humans. Cancer Immunology Immunothreapy 9: 187–192.Google Scholar
PMS report 1989 (no. 2): Pharmaceutical Affairs Bureau, Ministry of Health and Welfare Japan, 1134, December 20, 1989.Google Scholar
Saito, M., Ebina, T., Koi, M. (1982) Introduction of interferon in mice spleen cells by OK-432, a preparation of Streptococcus pyogenes. Cellular Immunology 68: 184–192.CrossRefGoogle Scholar
Saito, M., Yamaguchi, T., Ebina, T., Koi, M., Aonuma, E., Usami, H., Ishida, N. (1983) In vitro production of immune interferon (IFNr) by murine spleen cells when different sensitizing antigens are used in vitro. Cellular Immunology 78: 379–386.CrossRefGoogle Scholar
Saito, M., Nanjo, M., Aonuma, E., Noda, T., Nakadate, I., Ebina, T., Ishida, N. (1984) Activated macrophages are responsible for the tumour inhibitory effect in mice receiving intravenous injection of OK-432. International Journal of Cancer 33: 271–276.CrossRefGoogle ScholarPubMed
Saito, M., Nanjo, M., Kataoka, M., Moriya, Y., Sugawara, Y., Yoshida, T., Ishida, N. (1988) Adoptive immunotherapy by pantropic killer cells recovered from OK-432-injected tumour site in mice. Cancer Research 48: 4163–4169.Google Scholar
Uchida, A., Mickshe, M. (1983a) Lysis of fresh human tumour cells by autologous peripheral blood lymphocytes and plural effusion lymphocytes activated by OK 432. Journal of the National Cancer Institute 71: 673–680.Google Scholar
Uchida, A., Mickshe, M. (1983b) Lysis of fresh human tumour cells by autologous large granular lymphocytes from peripheral blood and plural effusions. International Journal of Cancer 32: 37–41.CrossRefGoogle Scholar
Wakasugi, H., Kasahara, T., Minato, N., Hamuro, J., Miyata, M., Morioka, Y. (1982) In vitro potentiation of human natural killer cell activity by a streptococcal preparation, OK-Interferon and Interleukin-2 participation in the stimulation with OK-432. Journal of the National Cancer Institute 69: 807–812.Google ScholarPubMed
Yamamoto, A., Nagamuta, M., Usami, H., Sugawara, Y., Watanabe, N., Niitsu, Y., Urushizaki, I. (1986) Release of tumour necrosis factor (TNF) into mouse peritoneal fluids by OK-432, a Streptococcal preparation. Immunopharmacology 11: 79–86.CrossRefGoogle ScholarPubMed
Yamashita, R., Hirooka, T., Kamimoto, I., Miyauchi, Y. (1986) Prevention of growth of metastasis in rat liver by perioperative immunoactivation. Cancer Research 46: 3138–3141.Google Scholar
Yamaue, H., Tanimura, H., Tsunoda, T., Iwahashi, M., Tani, M., Tamai, M., Noguchi, K., Hotta, T., Arii, K. (1992) Enhancement of tumour cell susceptibility to lymphokineactivated killer cells by treatment with the Streptococcal preparation OK-432. Biotherapy 5: 83–93.CrossRefGoogle Scholar